secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intra-Cellular Therapies, Inc. (—)
CIK:        0001567514
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001193125-24-132586
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intra-Cellular Therapies Q1: $144.8M CAPLYTA sales (+53% YoY), loss narrows; Ph3 MDD success
--------------------------------------------------------------------------------

- Net product sales of CAPLYTA $144.8M, up 53% from $94.7M YoY; net loss $15.2M vs $44.1M.
- Positive Phase 3 Study 501 results: lumateperone adjunctive MDD met primary (MADRS, p<0.0001) and key secondary endpoints.
- FY 2024 guidance reiterated: CAPLYTA sales $645-$675M, SG&A $450-$480M, R&D $215-$240M.
- Completed $543M net public offering of ~7.9M shares in April 2024; cash $477.4M at Q1 end.
- Expect to report Study 502 topline results late Q2 2024; sNDA filing planned H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567514/000119312524132586/0001193125-24-132586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567514/000119312524132586/d826948d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-132586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer